Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor
Active, not recruiting · Phase 2 · NCT02738866
Conditions: Metastatic Breast Cancer
At a glance
- Research payments reported, 2025
- $5,744
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 60
About the trial
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (with Pfizer)
- Tested
- Palbociclib (drug), Fulvestrant (drug)
- Dates
- Started 2016-10-25; completion 2026-12
- Results posted
- Not yet
This study is being done to look at the role of continuing palbociclib treatment in combination with another type of hormonal therapy (fulvestrant) after disease progression of palbociclib in combination with an aromatase inhibitor.
From ClinicalTrials.gov, last updated 2026-06-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Menarini Silicon Biosystems, Inc. reported $5,744 in research payments for this study in 2025 (1 payments).
Products named: Deparray
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.